Stocks · News reference
Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 11.63 percent increase over losses of $(0.86) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $55 price target.
8-K filing — Jade Biosciences, Inc. (JBIO)
Filed: 2026-09-30 AccNo: 0001193125-26-408287 Size: 162 KB Item 8.01: Other Events
Jade Biosciences Says Dermatomyositis Candidate JADE301 Showed About 25-Day Half-Life In Primates; Expects Phase 1 Start In Q4 2026